Nykode Therapeutics presents additional efficacy analysis in

Nykode Therapeutics presents additional efficacy analysis in Phase 2 study of VB10.16 in combination with atezolizumab in advanced cervical cancer

07.11.2022 - Results show strong signals of clinical responses in patients with advanced cervical cancer who received up to 2 prior lines of therapyOSLO, Norway, Nov. 07, 2022 (GLOBE NEWSWIRE) - Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage ... Seite 1

Related Keywords

Michael Engsig , , Executive Officer , Objective Response , Suisse Annual Healthcare Conference ,

© 2025 Vimarsana